TD Asset Management Inc Cuts Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

TD Asset Management Inc lowered its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 19.4% in the fourth quarter, Holdings Channel reports. The firm owned 376,344 shares of the company’s stock after selling 90,616 shares during the period. TD Asset Management Inc’s holdings in Centessa Pharmaceuticals were worth $9,412,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of CNTA. TD Waterhouse Canada Inc. purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth about $25,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares in the last quarter. DNB Asset Management AS purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $218,000. Sigma Planning Corp purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth about $225,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $455,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at $1,735,805.25. The trade was a 52.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider owned 62,085 shares in the company, valued at $1,629,731.25. The trade was a 65.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 309,112 shares of company stock worth $8,424,535 over the last 90 days. 4.09% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of research reports. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research note on Monday, April 13th. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Finally, Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $39.76 on Wednesday. The firm has a market capitalization of $5.93 billion, a PE ratio of -22.21 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $11.77 and a twelve month high of $40.26. The firm’s 50-day moving average price is $39.40 and its 200 day moving average price is $30.64. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, sell-side analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.